Jubilant Pharmova Ltd.
NSE: JUBLPHARMAJubilant Pharmova Ltd.: A 30-second snapshot
Jubilant Pharmova (JUBLPHARMA) trades at ₹1,004.4, up 16.23% over one year and 6.56% over three months, currently 19.52% below its 52-week high. At a trailing PE of 36.4 (forward PE 27.3), the stock sits between sector peers — below APOLLOHOSP (64.6x) and MAXHEALTH (72.5x), and above CIPLA (29.8x) and Dr. Reddy's (26.6x) — against a backdrop of 5-year earnings declining 44.7% even as revenues grew 16.5%.
P/E
36.4
Forward P/E
27.3
ROE
—
Debt / Equity
43.87
Profit Margin
+5.5%
Div. Yield
+0.5%
5Y ROE > 15%
0/5
5Y FCF > 0
2/5
Quality
39/100
Recent context
- ·Zero news items were retrieved for this run date, so no recent corporate events, regulatory actions, or product pipeline announcements can be assessed.
- ·The stock is 19.52% below its 52-week high despite a 16.23% one-year gain, indicating it reached a materially higher point during the period and has since corrected.
- ·Analyst data is limited to 2 respondents with no consensus rating available, making sell-side signal thin relative to the 6-peer sector comparison set.
Strengths
- +5-year revenue CAGR of 16.5% demonstrates consistent top-line expansion over the measured period.
- +Forward PE of 27.3 represents a 25% compression from the trailing PE of 36.4, implying the market prices in meaningful earnings recovery in the near term.
- +Price is above the 50-DMA of ₹888.87 — a 13% premium — showing recent price recovery from lower levels.
- +Stock is ranked 3rd of 6 sector peers on PE, sitting in the mid-range rather than at an extreme valuation premium.
Weaknesses
- −Earnings declined 44.7% over 5 years against 16.5% revenue growth — a divergence that indicates either structural margin erosion or material one-off charges compressing profitability.
- −Debt-to-equity of 43.867 is among the highest in the pharma peer set; FCF was positive in only 2 of the measured years, limiting the buffer available for debt service or reinvestment.
- −ROE has not cleared 15% in any measured year; consistency score of 43 and quality score of 36 rank 4th of 6 peers, placing the company in the lower half of the sector on capital efficiency.
- −Current price of ₹1,004.4 remains below the 200-DMA of ₹1,022.91; RSI at 71.12 signals overbought conditions simultaneously, a combination that historically reflects near-term extension rather than trend restoration.
Open questions
- ?Does the 44.7% earnings decline over 5 years reflect identifiable one-time charges — such as impairments or restructuring — or does it signal a structurally narrowing moat in the company's therapeutic areas?
- ?How does the company's debt-to-equity of 43.867 compare against its interest coverage ratio, and what proportion of FCF in positive years was consumed by debt servicing?
- ?Is the forward PE compression from 36.4x to 27.3x driven by consensus earnings growth forecasts, or does it rest on a small analyst base (n=2) with limited coverage breadth?
- ?What accounts for the price recovering above the 50-DMA while remaining below the 200-DMA — is recent momentum driven by sector rotation, company-specific news, or broader market conditions?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| JUBLPHARMA | Jubilant Pharmova Ltd.You're viewing | 36.4 | — | 36 |
| Industry avg | across 5 peers | 47.0 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.5 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.6 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.6 | +11.8% | 17 |
Technical state
Current price
₹1,004.40
SMA 50
₹888.87
SMA 200
₹1,022.91
RSI (14)
71.1 (overbought)
From 52w high
-19.5%
1Y return
+16.2%
3M return
+6.6%
50-DMA
Above
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highEarnings declined 44.7% over 5 years against 5-year revenue growth of 16.5%; profit margin stands at 5.46%, signalling severe compression in earnings conversion from top-line expansion.
- highDebt-to-equity of 43.867 is extremely elevated for a pharma company; FCF was positive in only 2 of the measured years, raising material questions about debt serviceability.
- mediumROE has never cleared 15% in any measured year (roeYearsAbove15 = 0); quality score of 36 ranks 4th of 6 sector peers.
- mediumCurrent price of ₹1,004.4 is below the 200-DMA of ₹1,022.91 while RSI is 71.12 (overbought territory), indicating near-term momentum extension against a sub-200-DMA structure.
- lowZero news items retrieved; no sentiment data available, leaving recent corporate developments unobserved.
Cross-section contradictions
- 5-year revenue CAGR of 16.5% alongside a 44.7% decline in 5-year earnings presents a stark divergence — significant cost escalation, one-off charges, or structural margin compression is embedded in these numbers.
- RSI at 71.12 (overbought) while price remains below the 200-DMA of ₹1,022.91 — short-term momentum is elevated, yet the medium-term trend structure has not recovered its long-run average.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 15 May 2026 · rotates through NIFTY 500 every ~5 days